VKTX · Viking Therapeutics, Inc.
$24.40
-5.54% last session
End-of-day data · close of 2026-10-23
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-5.6
Dividend yield
0.0%
Beta
0.65
Avg volume
5M
Employees
0K
Daily Change %
-5.54%
5 Days Change
2.62%
10 Days Change
-3.08%
30 Days Change
-37.98%
60 Days Change
-22.27%
Month to Day Change
-15.34%
Year to Day Change
-26.58%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VKTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-20
Latest call per bank · past 12 months
UBS
Buy$94.00
+285.2% vs priceJP Morgan
Overweight$65.00
+166.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Canaccord Genuity | Maintains | Buy | $114 → $106 |
| 2026-10-15 | UBS | Initiates | Buy | $0.00 → $94.00 |
| 2026-10-07 | Truist Securities | Maintains | Buy | $87.00 → $85.00 |
| 2026-09-23 | Truist Securities | Maintains | Buy | $83.00 → $87.00 |
| 2026-08-11 | JP Morgan | Maintains | Overweight | $75.00 → $65.00 |
| 2026-07-30 | Canaccord Genuity | Maintains | Buy | $107 → $114 |
| 2026-05-28 | Lake Street | Initiates | Buy | $0.00 → $89.00 |
| 2026-05-01 | BTIG | Reiterates | Buy | $125 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 22.2% below the 50-day MA ($31.35).
- bearish: Price vs 200-day MA: Trading 25.1% below the 200-day MA ($32.56).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.18) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($24.40).
VKTX Price Chart
Loading chart for VKTX…
Fundamentals
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.